Keith Westby - Apr 3, 2023 Form 4 Insider Report for IVERIC bio, Inc. (ISEE)

Role
SVP, Chief Operating Officer
Signature
/s/ Todd D.C. Anderman, as Attorney-in-Fact for Keith Westby
Stock symbol
ISEE
Transactions as of
Apr 3, 2023
Transactions value $
-$1,068,194
Form type
4
Date filed
4/5/2023, 06:48 PM
Previous filing
Mar 6, 2023
Next filing
Apr 25, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ISEE Common Stock Options Exercise $20K +13.8K +34.77% $1.45* 53.4K Apr 3, 2023 Direct F1
transaction ISEE Common Stock Options Exercise $18.3K +6.21K +11.63% $2.94* 59.7K Apr 3, 2023 Direct F1
transaction ISEE Common Stock Options Exercise $90.4K +20K +33.53% $4.52* 79.7K Apr 3, 2023 Direct F1
transaction ISEE Common Stock Sale -$460K -17.5K -21.93% $26.35 62.2K Apr 3, 2023 Direct F1, F2
transaction ISEE Common Stock Sale -$608K -22.5K -36.23% $26.98 39.7K Apr 3, 2023 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ISEE Stock Option (right to buy) Options Exercise -$20K -13.8K -100% $1.45* 0 Apr 3, 2023 Common Stock 13.8K $1.45 Direct F1, F4
transaction ISEE Stock Option (right to buy) Options Exercise -$18.3K -6.21K -4.25% $2.94* 140K Apr 3, 2023 Common Stock 6.21K $2.94 Direct F1, F5
transaction ISEE Stock Option (right to buy) Options Exercise -$90.4K -20K -41% $4.52* 28.8K Apr 3, 2023 Common Stock 20K $4.52 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale reported on this form was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 16, 2022.
F2 The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions effected at prices ranging from $25.66 to $26.65 per share on April 3, 2023. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Registrant or a security holder of the Registrant, information regarding the number of shares sold at each price within the range.
F3 The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions effected at prices ranging from $26.66 to $27.00 per share on April 3, 2023. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Registrant or a security holder of the Registrant, information regarding the number of shares sold at each price within the range.
F4 This stock option award was granted on December 12, 2018 and vested with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares in approximately equal monthly installments through the fourth anniversary of the grant date.
F5 This stock option award was granted on December 19, 2017 and vested with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares in approximately equal monthly installments through the fourth anniversary of the grant date.
F6 This stock option award was granted on January 30, 2017 and vested with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares in approximately equal monthly installments through the fourth anniversary of the grant date.